The use of beta-blockers is associated with the occurrence of @entity810 in severe XXXX .

@entity1 @entity82 @entity810 @entity99
BACKGROUND _ AIMS: The beneficial effect of nonselective beta-blockers (NSBB) has recently been questioned in @entity1 with end-stage @entity82 . We analysed the impact of NSBB on outcomes in severe @entity99 ( @entity99 ). METHODS: This study was based on a prospective database of @entity1 with severe, biopsy-proven @entity99 . @entity1 admitted from July, 2006 to July, 2014 were retrospectively studied. @entity1 were divided into two groups (with and without NSBB) and assessed for the occurrence of @entity810 ( @entity810 ) and transplant-free mortality during a 168-day follow-up period. RESULTS: One hundred thirty-nine @entity1 were included, the mean Maddrey score was 71      34 and 86 @entity1 (61.9%) developed @entity810 . Forty-eight @entity1 (34.5%) received NSBB. The overall 168-day transplant-free mortality was 50.5% (95%CI, 41.3-60.0%). The overall 168-day cumulative incidence of @entity810 was 61.9% (95%CI, 53.2-69.4%). When compared, @entity1 with NSBB had a lower heart rate (65      13 vs 92      12, P  <  0.0001) and a lower mean arterial pressure (MAP, 78      3 vs 87      5, P  <  0.0001). @entity1 with NSBB had comparable MELD scores, Maddrey scores, and medical histories. The 168-day transplant-free mortality was 56.8% (95%CI, 41.3-69.7%) in @entity1 with NSBB and 46.7% (95%CI, 35.0-57.6%) without NSBB (P  =  0.25). The 168-day cumulative incidence of @entity810 was 89.6% (95%CI, 74.9-95.9%) with NSBB compared to 50.4% (95%CI: 39.0-60.7) for no NSBB (P  =  0.0001). The independent factors predicting @entity810 were a higher MELD score and the presence of NSBB. CONCLUSIONS: The use of NSBB in @entity1 with severe @entity99 is independently associated with a higher cumulative incidence of @entity810 .
